- Home
- IMVT
IMVT
Immunovant Inc.
as 02-21-2025 4:00pm EST
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 3.6B | IPO Year: | N/A |
| Target Price: | $45.90 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 12 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $19.07 - $39.55 | Next Earning Date: | 02-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Immunovant Inc. (IMVT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Geffner Michael | IMVT | Chief Medical Officer | Jan 22 '25 | Sell | $23.59 | 2,657 | $62,678.63 | 132,314 | |
| Stout Jay S | IMVT | Chief Technology Officer | Jan 22 '25 | Sell | $23.59 | 2,195 | $51,780.05 | 139,991 | |
| Macias William L. | IMVT | Chief Medical Officer | Jan 15 '25 | Sell | $24.00 | 2,383 | $56,782.17 | 359,908 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Jan 15 '25 | Sell | $24.00 | 2,298 | $54,756.80 | 324,766 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Jan 15 '25 | Sell | $24.00 | 8,767 | $208,899.97 | 964,225 | |
| Roivant Sciences Ltd. | IMVT | Director10% Owner | Jan 13 '25 | Buy | $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | |
| Barnett Eva Renee | IMVT | Chief Financial Officer | Jan 8 '25 | Sell | $24.10 | 4,105 | $98,930.50 | 324,766 | |
| Salzmann Peter | IMVT | Chief Executive Officer | Jan 8 '25 | Sell | $24.10 | 5,105 | $123,030.50 | 964,225 | |
| Hughes Douglas J. | IMVT | Director | Dec 2 '24 | Sell | $28.54 | 5,425 | $154,829.50 | 119,585 | |
| Pande Atul | IMVT | Director | Dec 2 '24 | Sell | $28.54 | 7,750 | $221,185.00 | 86,663 |
Latest Immunovant Inc. News
IMVT Breaking Stock News: Dive into IMVT Ticker-Specific Updates for Smart Investing
Insider Monkey
12 hours ago
Immunovant, Inc. (IMVT): Is It The Most Oversold Healthcare Stock to Buy Now?
MT Newswires
21 hours ago
Immunovant Insider Sold Shares Worth $322,058, According to a Recent SEC Filing
Insider Monkey
3 days ago
Immunovant, Inc. (IMVT): Among Stocks Insiders Spent The Most Money On Recently
TipRanks
10 days ago
Roivant Sciences price target lowered to $12 from $13 at BofA
Zacks
10 days ago
Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Thomson Reuters StreetEvents
12 days ago
Q3 2024 Roivant Sciences Ltd Earnings Call
MT Newswires
12 days ago
Oppenheimer Adjusts Price Target on Immunovant to $54 From $53, Keeps Outperform Rating
Zacks
15 days ago
IMVT Q3 Loss Wider Than Expected, Stock Down, Pipeline in Focus
Compare IMVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMVT Immunovant Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.